Inhaled Corticosteroids and LABAs — Removal of the FDA’s Boxed Warning

For years, the risks associated with the use of long-acting beta-agonists (LABAs) in patients with asthma have been uncertain, and some health care professionals have recommended conducting large clinical trials to gather important safety information on these products. In December 2017, the Food…

Read the full post at The New England Journal of Medicine: Search Results in Health Policy and Reform
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive